# A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy

> **NCT01769547** · PHASE2 · TERMINATED · sponsor: **Ontario Clinical Oncology Group (OCOG)** · enrollment: 12 (actual)

## Conditions studied

- Advanced Malignant Pleural Mesothelioma
- MPM

## Interventions

- **DRUG:** Dovitinib

## Key facts

- **NCT ID:** NCT01769547
- **Lead sponsor:** Ontario Clinical Oncology Group (OCOG)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-03
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Stage 1 accrual completed. Study did not proceed to Stage 2 accrual.
- **Last updated:** 2015-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01769547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01769547, "A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01769547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*